Search

Displaying results 3691 - 3700 of 10000 in total
  1. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

  2. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    _C. botulinum_ is known to produce toxins that can cause botulism in humans. … It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil.

  3. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

  4. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Flulaval Quadrivalent 2020/2021
  5. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  6. Drug

    Staurosporine

    go.drugbank.com/drugs/DB02010
    Experimental

    An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)

  7. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo … Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730].

  8. Drug

    Aspergillus flavus

    go.drugbank.com/drugs/DB10694
    Approved

    Aspergillus flavus extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  9. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens

  10. Drug

    Penicillium camemberti

    go.drugbank.com/drugs/DB10809
    Approved

    Penicillium camemberti extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture